CRSP - Is bluebird bio a Bad News Buy?
bluebird bio (NASDAQ: BLUE) ran into some issues with manufacturing its gene therapy, and then the drugmaker was sideswiped by the possibility that its treatment might cause cancer. In this video from Motley Fool Live , recorded on Mar ch 22 , Fool.com contributors Brian Orelli and Keith Speights discuss the biotech's issues and how the concerns may already be priced into the company's valuation. On the downside, Bluebird has lost its lead on companies such as CRISPR Therapeutics (NASDAQ: CRSP) , which has already generated early clinical data for its gene-editing therapy for beta thalassemia and sickle cell disease that will compete against Bluebird's betibeglogene.
For further details see:
Is bluebird bio a Bad News Buy?